| 王 卓,赵雪英,谷 俊,荆志强,王慧敏.金水宝胶囊联合匹多莫德治疗支气管哮喘疗效及对免疫系统、血清 TNF-α水平影响[J].,2021,(11):2089-2093 |
| 金水宝胶囊联合匹多莫德治疗支气管哮喘疗效及对免疫系统、血清 TNF-α水平影响 |
| The Effect of Jinshuibao Capsule Combined with Pidomod on Bronchial Asthma and Its Effect on Immune System and Serum TNF-α Level |
| 投稿时间：2020-09-24 修订日期：2020-10-18 |
| DOI：10.13241/j.cnki.pmb.2021.11.020 |
| 中文关键词: 金水宝胶囊 匹多莫德 支气管哮喘 免疫系统 TNF-α |
| 英文关键词: Jinshuibao capsules Pidomod Bronchial asthma Immune system TNF-α |
| 基金项目:陕西省中医管理局中医药科研项目（JCPT044） |
|
| 摘要点击次数: 905 |
| 全文下载次数: 525 |
| 中文摘要: |
| 摘要 目的：探究金水宝胶囊联合匹多莫德治疗支气管哮喘的临床疗效，以及治疗前后对患者免疫系统、血清肿瘤坏死因子（tumor necrosis factor-α，TNF-α）水平的影响。方法：选择2017年1月至2019年10月于我院接受治疗的62例支气管哮喘患者为研究对象，按照其选择治疗方式的差异将其分为实验组与对照组（每组各31例患者），对照组患者在常规治疗基础上加用匹多莫德，实验组患者在对照组基础上联用金水宝胶囊，对比两组患者治疗效果、治疗前后免疫细胞因子变化情况、肺功能变化以及炎症因子水平变化。结果：实验组治疗有效率为96.77 %，对照组为80.65 %，两组比较差异明显（P<0.05）。治疗前两组CD3+、CD4+、第1秒用力呼气容积占预计值百分比（forced expiratory volume in the first second，FEV1%）、呼气峰流量（peak expiratory flow，PEF）、哮喘控制测试（asthma control test，ACT）、TNF-α和hs-CRP水平比较差异不大（P>0.05），治疗后实验组CD3+、CD4+、FEV1%、PEF和ACT均高于对照组（P<0.05），TNF-α、hs-CRP水平均低于对照组（P<0.05）。结论：金水宝胶囊联合匹多莫德对支气管哮喘具有较好的治疗效果，能够显著改善患者的免疫机能和肺功能，同时改善机体炎症状态，值得进行临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of Jinshuibao capsule combined with pidomod in the treatment of bronchial asthma, and the effect of treatment on the patient's immune system and serum TNF-α level. Methods: 62 patients with bronchial asthma who were treated in our hospital from January 2017 to October 2019 were selected as the research object, and they were divided into an experimental group and a control group according to the differences in the treatment options (31 patients in each group), Patients in the control group added pidomod on the basis of conventional treatment, and patients in the experimental group were combined with Jinshuibao capsules on the basis of the control group to compare the treatment effect, changes in immune cytokines, changes in lung function and before and after treatment in the two groups. Changes in inflammatory factor levels. Results: The effective rate of treatment in the experimental group was 96.77 %, and the control group was 80.65 %. The difference between the two groups was significant (P<0.05). Before treatment, the levels of CD3+, CD4+, FEV1%, PEF, ACT, TNF-α and hs-CRP were not significantly different (P>0.05). After treatment, the CD3+, CD4+, FEV1%, PEF and ACT of the experimental group were higher than the control group (P<0.05), and the levels of TNF-α and hs-CRP were lower than the control group (P<0.05). Conclusion: Jinshuibao capsule combined with pidomod has a good therapeutic effect on bronchial asthma, can significantly improve the patient's immune function and lung function, and improve the body's inflammatory state at the same time, which is worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
